Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas
Sponsor: Anne Chang
Terminated
Business Decision
A PHASE2 clinical study on Basal Cell Nevus Syndrome and Carcinoma, Basal Cell, this trial is terminated or withdrawn. The trial is conducted by Anne Chang and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed · Phase: NA → PHASE2
-
May 2017 — May 2018 [monthly]
Active Not Recruiting NA
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Feb 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anne Chang
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .